摘要
目的分析联合应用托特罗定与多沙唑嗪治疗TURP术后膀胱过度活动症的临床疗效。方法 80例行TURP的前列腺增生患者按就诊顺序随机分为4组,每组20例,自手术当日起分别单纯给予口服托特罗定、多沙唑嗪、安慰剂及托特罗定联合多沙唑嗪直至拔除导尿管后1周。于拔除尿管后第1天,第7天检测各组最大尿流率(Qmax),并通过调查问卷的形式,记录各组IPSS储尿期分数,以及各组平均每天发生的尿急次数,24小时排尿次数,夜尿次数及用药后不良反应。结果拔除导尿管后第1天、第7天各组平均Qmax无显著性差异(P>0.05);拔除导尿管后第1天、第7天托特罗定联合多沙唑嗪组及托特罗定组平均IPSS储尿期分数、平均尿急次数、24小时排尿次数与安慰剂组相比均有明显改善(P<0.05);拔除导尿管后第7天托特罗定联合多沙唑嗪组平均夜尿次数与托特罗定组、安慰剂组相比有显著改善(P<0.05),各组不良反应均可耐受。结论托特罗定联合多沙唑嗪对于治疗TURP术后的膀胱过度活动症临床疗效确切,其效果优于单独应用托特罗定,且治疗过程中无严重不良反应发生,是一种安全、有效的治疗方案。
Objective To evaluate the efficacy and safety of tolterodine plus doxazosin on BPH Patients with overactive bladder(OAB) immediately after Transurethral Resection of Prostate(TURP) Methods 80 benign prostatic hyperplasia(BPH) patients treated with TURP were randomized to placebo,tolterodine,doxazosin or tolterodine plus doxazosin.Assessments included Qmax,IPSS storage subscores,urgency,frequency,nocturna and adverse reactions,according to questionnaire in the first and seventh day after removal of the catheter.Results There were no statistically significant difference in Qmax among the 4 groups,patients receiving tolterodine or tolterodine plus doxazosin had significantly greater improvements than those taking placebo on IPSS storage subscale scores,urinary frequency and urgency in the first and seventh day,nocturnal micturitions in tolterodine plus doxazosin group were significantly improved compared with tolterodine or placebo group at the seventh day. No serious adverse reaction occurred.Conclusions Tolterodine plus doxazosin was efficacious in BPH Patients with OAB immediately after TURP.It is an effective treatment regine for such patients and was more effective than tolterodine monotherapy.
出处
《泌尿外科杂志（电子版）》
2009年第2期30-34,共5页
Journal of Urology for Clinicians(Electronic Version)
